Publications

Dendritic cell vaccines

Bigalke I., Eckl J., Solum G., Hønnåshagen K., Skoge L., Fløisand Y., Josefsen D., Sæbøe-Larssen S., Geiger C., Schendel D., Kvalheim G. 2018. Immune Monitoring of Vaccine Quality and Persistence of Specific T Cell Responses in Five AML Patients Receiving Extended Dendritic Cell Vaccination Under Compassionate Use

Download PDF

 

Subklewe M., Geiger C., Lichtenegger F.,  Javorovic M., Kvalheim G., Schendel D.J., Bigalke I. 2014. New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. Cancer Immunology. 10.1007/s00262-014-1600-5

Download PDF


Lichtenegger, F. S., Mueller, K., Otte, B., Beck, B., Hiddemann, W.,  Schendel, D. J. and M. Subklewe. 2012. CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells. PLoS One. 7(9): e44266.

Further information


Spranger, S., Frankenberger, B. and D. J. Schendel. 2012. NOD/scid IL-2Rgnull mice: a pre-clinical model system to evaluate human dendritic cell-based vaccine strategies in vivo.  J Transl. Med. 10(1): 30. [Epub ahead of print]

Further information


Frankenberger, B. and D.J. Schendel. 2012. Third generation dendritic cell vaccines for tumor immunotherapy. Eur. J. Cell Biol. 91(1): 53-58 [Epub 2011 Mar 25]

Further information


Beck, B., Dörfel, D., Lichtenegger, F.S., Geiger, C., Lindner, L., Merk, M., Schendel, D.J., and M. Subklewe. 2011. Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. J. Transl. Med. 9:151 [Epub. Sep. 13]

Further information


Bürdek M., Spranger S., Wilde S., Frankenberger B., Schendel D.J. and C. Geiger. 2010 Three-day dendritic cells for vaccine development: Antigen uptake, processing and presentation. J. Transl. Med. 8:90.

Further information


Spranger, S., Javorovic, M., Bürdek, M., Wilde, S., Mosetter, B., Tippmer, S., Bigalke, I., Geiger, C., Schendel, D.J. and B. Frankenberger. 2010. Generation of T helper-1 polarizing dendritic cells using the Toll-like receptor 7/8 agonist CL075. J. Immunol. 185(1): 738-747. 

Further information


Javorovic, M., Wilde, S., Zobywalski, A., Noessner, E., Lennerz, V., Wölfel, T., and D.J. Schendel. 2008. Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells. J. Immunother 31(1): 52-62. 

Further information


Zobywalski, A., Javorovic, M., Frankenberger, B., Pohla, H., Kremmer, E., Bigalke, I. and D.J. Schendel. 2007. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J. Transl Med. 5:18 (highly accessed).

Further information


T cell receptor (TCR)-modified T cells for adoptive T cell therapy

Jaravine, V., Raffegerst, S., Schendel, DJ., Frishman, D. Assessment of cancer and virus antigens for cross-reactivity in human tissues Bioinformatics 2017 Jan 1;33(1):104-111. doi: 10.1093/bioinformatics/btw567.

Further Information


Schlenker, R., Olguín-Contreras, L., Leisegang, M., Schnappinger, J., Disovic, A., Rühland, S., Nelson, P., Leonhardt, H., Harz, H., Wilde, S., Schendel, D. Uckert, W., Willimsky, G. and Noessner, E. Cancer Research, 2017. Chimeric PD-1:28 receptor upgrades low-avidity T cells and restores effector function of tumor-infiltrating lymphocytes for adoptive cell therapy

Further information


Haase, K., Raffegerst, S., Schendel, D., Frishman, D. Expitope: a web server for epitope expression. Bioinformatics. 2015 Jun 1;31(11):1854-6. doi: 10.1093/bioinformatics/btv068.

Further information


Obenaus, M., Leitão, C., Leisegang, M., Chen, X., Gavvovidis, I., van der Bruggen, P., Uckert, W., Schendel, D.J. and Blankenstein, T. 2015. Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice. Nature Biotechnology 33, 402–407 (2015).

Further information


Schendel, D.J. and P.D. Greenberg. 2014. The ABC’s of T cell receptor gene therapy. In: Cancer Immunotherapy Meets Oncology (Britten, C.M., Kreiter, S., Diken, M., Rammensee, H.-G., Eds). Pp. 117-126. Springer International Publishing, Switzerland, Heidelberg, Dordrecht, London, New York, 25.05.2014. 

Further information


Pinto, S., Sommermeyer, D., Michel, C., Wilde, S., Schendel, D, Uckert, W., Blankenstein T., Kyewski, B. 2014. Mis-initiation of MART-1 transcription in the thymus and biased TCR usage can explain the high frequency of peripheral MART-1 specific T cells. Eur J Immunol. 2014 May 20 [Epub ahead of print].

Further information


Schendel, D.J. and Frankenberger, B. 2013. Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity. Oncoimmunology. 2013 Jan 1; 2(1):e22410.

Further information


Morgan, R. A., Chinnasamy, N.,  Abate-Daga, D.,  Gross, A., Robbins, P. F.,  Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., Phan, G., Hughes, M. S.,  Kammula, U. S., Miller, A., Hessman, C., Stewart, A., Restifo, R., Quezado, M. M. (+ other members of Pathology staff), Nath, A., Wang, D., Bielekova, B., Wuest, S., Nirmala, A., (+ others, NIMH deep sequencing group), Schendel, D. J., Wilde, S., Mosetter, B., Laurencot, C. and Rosenberg, S. A. 2013. Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 36(2):133-151.

Further information


Wilde, S. and D.J., Schendel. 2012. High-quality and high-avidity T cell clones specific for tumor-targeted antigens and how to find them. Oncoimmunology. 1(9):1643-1644.

Further information

Wilde, S., Sommermeyer, D., Leisegang, M., Frankenberger, B., Mosetter, B., Uckert, W. and D. J. Schendel. 2012. Human antitumor CD8+ T cells producing Th1-polycytokines show superior antigen sensitivity and tumor recognition. J Immunol. 189(2): 598-605.

Further information


Wilde, S., Geiger, C., Milosevic, S., Mosetter, B., Eichenlaub, S. and D.J. Schendel. 2012. Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: A three phase experimental procedure. Oncoimmunology. 1(2): 129-140.

Further information


Spranger, S., Jeremias, I., Wilde, S., Leisegang, M., Stärck, L., Mosetter, B., Uckert, W., Heemskerk, M., *Schendel, D. J. and B. *Frankenberger. 2012. T cell receptor-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo. (* equal senior authors) Blood. 119(15): 3440-3449. [Epub ahead of print].

Further information


Leisegang M., Wilde S., Spranger S., Milosevic S., Frankenberger B., Uckert W. and D.J. Schendel. 2010. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J. Clin. Invest. 120 (11): 3869-3877.

Further information


Wilde, S., Sommermeyer, D., Frankenberger, B., Schiemann, M., Milosevic, S., Spranger, S., Pohla, H., Uckert, W., Busch, D.H. and D.J. Schendel. 2009. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior anti-tumor activity and higher TCR functional avidity. Blood 114(10): 2131-2139.

Further information


Becker, C., Pohla, H., Frankenberger, B., Schüler, T., Assenmacher, M., Schendel, D.J. and Blankenstein, T. 2001. Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay. Nat Med.; 7 (10):1159–1162.

Further information